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Epilepsy is a set of neurological disorders
affecting about 1% of world human population. The
disorders have various etiology and progress, result-
ing in clinically different seizures, which start in the
cerebral cortex. Despite great development of phar-
macotherapy of epilepsy, about 30% of all seizures
are resistant to drugs. Moreover, many patients who
manage to control the symptoms using two or three
medicines face numerous side effects enlarged by
drug interactions. Therefore, there are strong prem-
ises for further research in this field (1, 2).
Currently available antiepileptic drugs (AEDs)
have been mostly discovered by means of the maxi-
mum electroshock (MES), subcutaneous pentetra-
zole (scMet), and rotarod neutoroxicity (TOX)
screens. However, pathophysiology of drug-resist-
ant seizures does not resemble mechanism of the
above stimuli, therefore 6 Hz test was introduced. It
has been proved that it mimics epileptogenesis ñ the
process where damaged neuronal tissue exhibits
pathological processes leading to epilepsy.
Examples of drugs active in 6 Hz test and inactive in
MES are levetiracetam and its analog ñ seletracetam
(3, 4). 
Research concerning anticonvulsant activity of
well-known antiarrhythmic drugs, such as propra-
nolol and mexiletine (Fig. 1), has revealed that both
these medicines prevent seizures in the maximum
electroshock seizure test (MES, mice, i.p.). Among
the likely mechanisms in both cases there is inhibi-
tion of sodium channels, apart from their main
molecular mechanisms (blocking β-adrenergic
receptors and opening potassium channels, respec-
tively) (5, 6). The effect of potential stabilization
within neurons by those two drugs was a starting
point for searching new anticonvulsant compounds
among aroxyalkylaminoalkanols (7). 
In our previous studies (8ñ14), we reported
anticonvulsant activity of some amido- and
aminoalkanols which were examined within the
Anticonvulsant Screening Program (ASP) carried
out at National Institute of Neurological Disorders
and Stroke, National Institutes of Health, Rockville,
USA (15). One of them, (S)-(+)-2-N-[(2,6-dimethyl-
phenoxy)ethyl]aminobutan-1-ol hydrochloride dis-
played sufficient protection against MES-induced
seizures and low toxicity (mice, i.p.) with ED50 =
7.57 mg/kg and PI = 4.55 (8). Another compound,
(R,S)-trans-2N-[(2,6-dimethylphenoxy)ethyl]
aminocyclohexan-1-ol exhibited ED50 = 7.73 mg/kg
and PI = 3.90 (MES, mice, i.p.) (Fig. 2) (9). We con-
sistently report lipophilicity parameters as important
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physicochemical feature in CNS drug discovery (10).
From the preliminary assay data, it was proposed that
anticonvulsant activity was associated mainly with
aminoalkanol type and configuration. Such anticon-
vulsant activity of the appropriate aminoalkanols
drew our attention onto influence of position and
type of substituents in the phenyl ring. So far, appro-
priate derivatives of 4-methylphenol, 2,6-
dimethylphenol (8, 9), 4-chlor-3-methylphenol and
2-chlor-5-methylphenol (10), as well as 4-chlor-2-
methylphenol (11) have been evaluated. Herein we
report results of synthesis and anticonvulsant screen-
ing of novel N-(2,3-dimethylphenoxy) and N-(2,3,5-
trimethylphenoxy)alkyl]aminoalkanols [IñXVII].
EXPERIMENTAL
Chemistry
Apparatus and reagents
Melting points (m.p.) were determined by
means of a B¸chi SMP-20 apparatus (B¸chi
Labortechnik, Switzerland) and are uncorrected.
Elemental analyses were performed on Vario El III
(Elementar Analyzensysteme GmbH, Germany).
Thin-layer chromatography was performed on pre-
coated aluminum sheets (silica gel 60 F254, Merck)
using mobile phase indicated below. The theoretical
values of the partition coefficient (LogP) of the test-
ed compounds were calculated by means of ACD-
Figure 1. Structures of cardiovascular drugs with anticonvulsant activity
Figure 2. Structures of (2,6-dimethylphenoxy)ethyl aminoalkanol derivatives with anticonvulsant activity
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Table 1. Chemical structures of the tested compounds [IñXVII].
R n Compound Z Configuration  
I R,S
II R,S
III R,S
2 IV R,S
V trans, R,S
2,5-(CH3)2 VI R,S
VII R,S
3 VIII R,S
IX trans, R,S
X R,S
XI R,S
XII R,S
2,3,5-(CH3)3 2 XIII R
XIV S
XV trans, R,S
XVI trans
XVII R,S
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LABS 12.0 program. Specific rotation (for com-
pounds XIII and XIV) was measured on Jasco P-
2000 polarimeter (1% w/v solutions in CH3OH, sodi-
um light 589 nm). The proton magnetic resonance
spectra were recorded by means of Varian VX 300
spectrometer (USA) or Bruker 500 spectrometer
(Germany) using DMSO-d6 or CDCl3 as solvents and
DMSO or TMS as internal standards, respectively.
The results are presented in the following format:
chemical shift δ (ppm), multiplicity, coupling con-
stants (J) values in Hertz (Hz), number of protons,
protonís position. Multiplicities are shown as the
abbreviations: s (singlet), bs (broad singlet), d (dou-
blet), dd (doublet of doublets), t (triplet), quin (quin-
tet), m (multiplet). D,L-trans-2-aminocyclohexan-1-
ol for synthesis of compounds V, IX and XV was
synthesized according to published procedures (9).
Other reagents were purchased from Alfa Aesar
(Germany) or Merck (Germany). Solvents were
commercially available materials of reagent grade. 
General procedure of synthesis of tested com-
pounds
The tested compounds were synthesized
according to formerly published procedures (7ñ10,
16). The general route of synthesis is shown in
Scheme 1 and the chemical structures of the tested
compounds in Table 1. 
First step of the synthesis included O-alkyla-
tion of 0.1 mole of appropriate substituted phenol:
2,5-dimethyl for compounds IñIX or 2,3,5-trimethyl
for compounds XñXVII with use of 10% excess of
2-chloroethanol (for IñVI and XñXVII) or 3-chloro-
propan-1-ol (for VIIñIX). The reaction was carried
out in 50% mixture of acetone with sodium
ethanolate or sodium propanolate, respectively, at
the presence of anhydrous K2CO3. The reaction mix-
ture was refluxed for 48 h. Then, it was filtered and
50 mL of 2% aqueous solution of NaOH was added
to the filtrate. The mixture was extracted with
toluene (2 ◊ 50 mL). Then, organic solvent was sep-
arated, dried over Na2SO4, and evaporated under
reduced pressure. Raw residue was used for bromi-
nation reaction by means of 10% excess of PBr3.
The reaction mixture was refluxed for 2 h in water
bath, then it was poured on ice. Raw product was
extracted by toluene, and the extract was dried over
anhydrous Na2SO4 and evaporated under reduced
pressure yielding bromide derivative. In the final
step, a mixture of 0.01 mole of an appropriate
aminoalkanol or amine and 0.01 mole of appropriate
bromide was refluxed for 6 h in 30 mL of toluene at
the presence of 0.015 mole of anhydrous K2CO3 as a
proton acceptor. Then, inorganic salts were filtered
off and organic solvent was evaporated under
reduced pressure. Oily residues were recrystallized
from toluene/n-heptane 1 : 5 v/v mixture. In order to
obtain compound XVII, the base was converted into
hydrochloride salt upon treatment with excess of
ethanolic solution of gaseous HCl. The hydrochlo-
ride was recrystallized from acetone.
R,S-1N-[(2,5-dimethylphenoxy)ethyl]amino-
propan-2-ol [I]
Yield 60%; C13H21NO2, M.w. = 223.31, m.p.:
64ñ66OC. Rf = 0.39 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 2.22 ± 0.28. 1H-NMR (500 MHz,
DMSO, δ, ppm: 6.98 (d, J = 7.4, 1H, Ar-H3); 6.73
(s, 1H, Ar-H6); 6.63 (d, J = 7.4 Hz, 1H, Ar-H4);
4.44 (d, J = 4.3 Hz, 1H, OH); 4.03ñ3.94 (m, 2H,
CH2-O); 3.71ñ3.64 (m, 1H, HO-CH); 2.88 (t, J = 5.5
Hz, 2H, O-CH2-CH2-N); 2.54ñ2.45 (m, 2H, N-CH2);
2.25 (s, 3H, Ar-CH3); 2.09 (s, 3H, Ar-CH3); 1.85 (bs,
1H, NH); 1.04 (d, J = 6.3 Hz, 2H, CH3-R). Analysis:
calcd.: C, 69.92; H, 9.48; N, 6.27%; found: C, 69.90;
H, 9.38; N, 6.21%.
Scheme 1. Synthesis of the tested compounds [IñXVII]
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R,S-2N-[(2,5-dimethylphenoxy)ethyl]amino-
propan-1-ol [II]
Yield 72%; C13H21NO2, M. w. = 223.31, m.p.:
74ñ76OC. Rf = 0.36 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 2.22 ± 0.28. 1H-NMR (500 MHz,
DMSO, δ, ppm): 6.98 (d, J = 7.4 Hz, 1H, Ar-H3);
6.73 (s, 1H, Ar-H6); 6.63 (d, J = 7.4 Hz, 1H, Ar-H4);
4.53 (t, J = 5.0 Hz, 1H, OH); 4.04ñ3.98 (m, 1H, 
O-CHH); 3.98ñ3.93 (m, 1H, O-CHH); 3.33ñ3.28
(m, 1H, N-CHH); 3.24ñ3.18 (m, 1H, N-CHH);
2.96ñ2.90 (m, 1H, CHHOH); 2.89ñ2.84 (m, 1H,
CHHOH); 2.71ñ2.64 (m, 1H, CH); 2.25 (s, 3H, Ar-
CH3); 2.10 (s, 3H, Ar-CH3); 1.88 (bs, 1H, NH); 0.92
(d, J = 6.3 Hz, 3H, CH3-R). Analysis: calcd.: C,
69.92; H, 9.48; N, 6.27%; found: C, 69.90; H, 9.32;
N, 6.19%.
R,S-2N-[(2,5-dimethylphenoxy)ethyl]aminobu-
tan-1-ol [III]
Yield 59%; C14H23NO2, M.w. = 237.34, m.p.:
66ñ68OC. Rf = 0.44 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 2.75 ± 0.28. 1H-NMR (500 MHz,
DMSO, δ, ppm): 6.98 (d, J = 7.4 Hz, 1H, Ar-H3);
6.73 (s, 1H, Ar-H6); 6.63 (d, J = 7.4 Hz, 1H, Ar-H4);
4.40 (t, J = 5.4 Hz, 1H, OH); 4.03ñ3.93 (m, 2H,
CH2-O); 3.42ñ3.22 (m, 2H, CH2-O); 2.90 (t, J = 5.5
Hz, 2H, N-CH2); 2.49ñ2.42 (m, 1H, CH); 2.25 (s,
3H, Ar-CH3); 2.09 (s, 3H, Ar-CH3); 1.76 (bs, 1H,
NH); 1.41ñ1.30 (m, 2H, R-CH2-R); 0.85 (t, J = 7.5
Hz, 3H, CH3-R). Analysis: calcd.: C, 70.85; H, 9.77;
N, 5.90%; found: C, 70.76; H, 9.69; N, 5.74%.
R,S-1N-[(2,5-dimethylphenoxy)ethyl]aminobu-
tan-2-ol [IV]
Yield 65%; C14H23NO2, M.w. = 237.34, m.p.:
63ñ65OC. Rf = 0.39 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 2.75 ± 0.28. 1H-NMR (500 MHz,
DMSO, δ, ppm): 6.97 (d, J = 7.4 Hz, 1H, Ar-H3);
6.73 (s, 1H, Ar-H6); 6.63 (d, J = 7.4 Hz, 1H, Ar-H4);
4.41 (bs, 1H, OH); 4.03ñ3.95 (m, 2H, O-CH2); 3.42
(bs, 1H, CH); 2.88 (t, J = 5.5 Hz, 2H, O-CH2-CH2-N);
2.57 (dd, J = 11.6, J = 4.0 Hz, 1H, N-CHH); 2.48
(dd, J = 11.6 Hz, J = 4.0 Hz, 1H, N-CHH); 2.26 (s,
3H, Ar-CH3); 2.10 (s, 3H, Ar-CH3); 1.84 (bs, 1H,
NH); 1.45ñ1.26 (m, 2H, CH2); 0.86 (t, J = 7.5 Hz,
3H, CH3-R). Analysis: calcd.: C, 70.85; H, 9.77; N,
5.90%; found: C, 70.80; H, 9.77; N, 5.78%.
R,S-trans-2N-[(2,5-dimethylphenoxy)ethyl]ami-
nocyclohexan-1-ol [V]
Yield 65%; C16H25NO2, M.w. = 263.38, m.p.:
99ñ101OC. Rf = 0.57 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 2.90 ± 0.27. 1H-NMR (300 MHz,
CDCl3, δ, ppm): 7.01 (d, J = 7.4 Hz, 1H, Ar-H4);
6.67 (d, J = 7.4 Hz, 1H, Ar-H3); 6.64 (s, 1H, Ar-H6);
4.05 (t, J = 5.4 Hz, 2H, O-CH2); 3.26ñ3.14 (m, 2H,
-CHH-NH + CH-OH); 2.92ñ2.85 (m, 1H, CHH-NH);
2.31 (s, 3H, Ar-CH3), 2.17 (s, 3H, Ar-CH3);
2.29ñ0.95 (m, 9H, cyclohexyl). Analysis: calcd.: C,
72.97; H, 9.57; N, 5.32%; found: C, 73.10; H, 9.83;
N, 5.49%.
R,S-2N-[(2,5-dimethylphenoxy)ethyl]amino-1-
phenylethan-1-ol [VI]
Yield 60%; C18H23NO2, M.w. = 285.38, m.p.:
124ñ126OC. Rf = 0.62 (CH3OH); Log P = 3.54 ±
0.30. 1H-NMR (500 MHz, DMSO, δ, ppm):
7.39ñ7.26 (m, 4H, Ar-H); 7.25ñ7.20 (m, 1H, Ar-H);
6.98 (d, J = 7.4 Hz, 1H, Ar-H3); 6.73 (s, 1H, Ar-H6);
6.63 (d, J = 7.4 Hz, 1H, Ar-H4); 5.26 (d, J = 3.5 Hz,
1H, OH); 4.68ñ4.61 (m, 1H, CH); 3.98 (t, J = 5.5 Hz,
2H, O-CH2); 2.92 (t, J = 5.5 Hz, 2H, O-CH2-CH2-N);
2.72 (d, J = 6.2 Hz, 2H, N-CH2-CH); 2.25 (s, 3H,
Ar-CH3); 2.05 (s, 3H, Ar-CH3); 1.89 (bs, 1H, NH).
Analysis: calcd.: C, 75.76; H, 8.12; N, 4.91%;
found: C, 75.49; H, 8.05; N, 4.90%.
R,S-2N-[(2,5-dimethylphenoxy)propyl]amino-
propan-1-ol [VII]
Yield 76%; C14H23NO2, M. w. = 237.34, m.p.:
80ñ81OC. Rf = 0.16 (CH3OH : ethyl acetate 1 : 1, v/v).
Log P = 2.47 ± 0.27. 1H NMR (500 MHz, DMSO, δ,
ppm): 7.00 (d, J = 7.44 Hz, 1 H, Ar-H3), 6.61ñ6.71
(m, 2 H, Ar-H4,6), 4.04 (t, J = 5.96 Hz, 2 H, 
O-CH2-CH2-CH2-N), 3.61 (dd, J = 10.64, 3.98 Hz, 1 H,
CH2-OH), 3.29 (dd, J = 10.77, 7.05 Hz, 1 H, CH2-OH),
2.98 (dt, J = 11.70, 6.91 Hz, 1 H, O-CH2-CH2-CH2-N),
2.73ñ2.91 (m, 2 H, O-CH2-CH2-CH2-N, CH-NH),
2.34 (bs, 2 H, OH, NH), 2.31 (s, 3 H, Ar-CH3), 2.17
(s, 3 H, Ar-CH3), 2.02 (quin, J = 6.41 Hz, 2 H, 
O-CH2-CH2-CH2-N), 1.10 (d, J = 6.54 Hz, 3 H, 
CH3-CH). Analysis: calcd.: C, 70,85; H, 9.77; N,
5.90%; found: C, 70.80; H, 9.61; N, 5.91%.
R,S-2N-[(2,5-dimethylphenoxy)propyl]aminobu-
tan-1-ol [VIII]
Yield 66%; C15H25NO2, M.w. = 251.36, m.p.:
53ñ54OC. Rf = 0.22 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 3.00 ± 0.27. 1H NMR (300 MHz,
CDCl3, δ, ppm): 7.00 (d, J = 7.4 Hz, 1H, Ar-H3),
6.71ñ6.61 (m, 2H, Ar-H4,6), 4.04 (t, J = 6.0 Hz, 2H,
Ar-O-CH2), 3.62 (dd, J = 10.5, J = 4.1 Hz, 1H, 
CH-CH2-OH), 3.27 (dd, J = 10.6, J = 6.6 Hz, 1H,
CH-CH2-OH), 2.97ñ2.86 (m, 1H, CH2-NH),
2.82ñ2.72 (m, 1H, CH2-NH), 2.61ñ2.51 (m, 1H,
NH-CH-CH2-OH), 2.31 (s, 3H, Ar-CH3), 2.17 (s, 3H,
Ar-CH3), 1.97 (quin, J = 6.4 Hz, 2 H, CH-CH2-CH3),
1.62ñ1.31 (m, 2H, O-CH2-CH2-CH2-NH), 0.91 (t, J
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= 7.5 Hz, 1 H, CH-CH2-CH3). Analysis: calcd.: C,
71.67; H, 10.02; N, 5.57%; found: C, 71.39; H, 9.95;
N, 5.51%.
R,S-trans-2N-[(2,5-dimethylphenoxy)propyl]ami-
nocyclohexan-1-ol [IX]
Yield 67%; C17H27NO2, M. w. = 277.41, m.p.:
92ñ93OC. Rf = 0.30 (CH3OH : ethyl acetate 1 : 1,
v/v). Log P = 3.15 ± 0.25. 1H NMR (500 MHz,
DMSO, δ, ppm): 7.00 (d, J = 7.6 Hz, 1H, Ar-H3),
6.71ñ6.60 (m, 2H, Ar-H4,6), 4.03 (t, J = 6.0 Hz, 2H,
Ar-O-CH2), 3.20ñ3.10 (m, 1H, cyclohexyl-H1/CH-OH),
3.03 (dt, J = 11.6, J = 6.9 Hz; 1 H, CH2-NH), 2.68
(dt, J = 11.6, J = 6.7 Hz, 1H, CH2-NH), 2.31 (s, 3H,
Ar-CH3), 2.26-2.18 (m, 1H, cyclohexyl-H2/CH-NH),
2.17 (s, 3H, Ar-CH3), 2.15ñ2.03 (m, 2H, cyclohexyl-
H6), 2.02ñ1.91 (m, 2H, cyclohexyl-H3), 1.78ñ1.66
(m, 2H, cyclohexyl-H5), 1.34ñ1.15 (m, 2H, cyclo-
hexyl-H4). Analysis: calcd.: C, 73.61; H, 9.81; N,
5.05%; found: C, 74.01; H, 9.84; N, 5.03%.
R,S-1N-[(2,3,5-trimethylphenoxy)ethyl]amino-
propan-2-ol [X]
Yield 69%; C14H23NO2, M.w. = 237.3, m.p.:
74ñ76OC. Rf = 0.52 (CH3OH : ethyl acetate 1 : 1, v/v).
Log P = 2.68 ± 0.28. 1H NMR (300 MHz, CDCl3, δ,
ppm): 6.62 (s, 1H, Ar-H4), 6.54 (s, 1H, Ar-H6), 4.05
(t, J = 5.1 Hz, 2H, O-CH2-CH2-N), 3.81 (quin, J = 9.4,
J = 6.3, J = 3.1 Hz, 1H, CH2-CH(OH)-CH3),
3.16ñ2.96 (m, 2H, O-CH2-CH2-N), 2.83 (dd, J =
12.1, J = 3.1 Hz, 1 H, CH2-CH(OH)-CH3), 2.56 (bs.,
2H, OH, NH), 2.49 (dd, J = 12.1, J = 9.5 Hz, 1 H,
CH2-CH(OH)-CH3), 2.28 (s, 3H, Ar-CH3), 2.23 (s,
3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3), 1.17 (d, J = 6.2
Hz, 3H, CH2-CH(OH)-CH3). Analysis: calcd.: C,
70.79; H, 9.77; N, 5.90%; found: C, 70.85; H, 9.46;
N, 5.59%.
R,S-2N-[(2,3,5-trimethylphenoxy)ethyl]amino-
propan-1-ol [XI]
Yield 62%; C14H23NO2, M.w. = 237.3, m.p.:
73ñ75OC. Rf = 0.25 (CH3OH : benzene (1 : 5, v/v).
Log P = 2.68 ± 0.28. 1H-NMR (300 MHz, CDCl3, δ,
ppm): 6.62 (s, 1H, Ar-H4); 6.54 (s, 1H, Ar-H6);
4.05ñ4.02 (m, 2H, Ar-O-CH2); 3.61 (dd, J = 4.1, J =
10.5 Hz, 1H, CHHOH); 3.27 (dd, J = 5.0, J = 10.5
Hz, 1H, CHHOH); 3.15ñ3.11 (m, 1H, CHH-N);
2.96ñ2.91 (m, 1H, CHH-N); 2.88ñ2.84 (m, 1H, 
N-CH); 2.28 (s, 3H, Ar-CH3); 2.23 (s, 3H, Ar-CH3);
2.10 (s, 3H, Ar-CH3); 1.10 (d, J = 6.5 Hz 3H, 
CH-CH3); 2.50ñ1.50 (bs, 2H, NH, OH). Analysis:
calcd.: C, 70.79; H, 9.77; N, 5.90%; found: C, 71.13;
H, 9.36; N, 5.78%.
R,S-2N-[(2,3,5-trimethylphenoxy)ethyl]aminobu-
tan-1-ol [XII]
Yield 60%; C15H25NO2, M.w. = 251.35, m.p.:
61ñ62OC (toluene : heptane 1 : 1, v/v); Rf = 0.63
(CH3OH : ethyl acetate 5 : 1, v/v). Log P = 3.21 ±
0.28. 1H-NMR (500 MHz, DMSO, δ, ppm): 6.59 (s,
1H, Ar-H4); 6.56 (s, 1H, Ar-H6); 4.45 (bs, 1H, OH);
3.95 (t, J = 5.3 Hz, 2H, Ar-O-CH2); 3.50ñ3.20 (m,
2H, CH2-OH); 2.90 (t, 2H, CH2-N); 2.55ñ2.40 (m,
1H, CH); 2.21 (s, 3H, Ar-CH3); 2.16 (s, 3H, Ar-CH3);
2.02 (s, 3H, Ar-CH3); 1.45ñ1.3 (m, CH2-CH3); 0.85
(t, J = 7.2 Hz, 3H, CH2-CH3). Analysis: calcd.: C,
71.68; H, 10.03; N, 5.57%; found: C, 71.30; H, 9.90;
N, 5.54%.
R-(-)-2N-[(2,3,5-trimethylphenoxy)ethyl]amino-
butan-1-ol [XIII]
Yield 58%; C15H25NO2, M.w. = 251.35, m.p.:
47ñ49OC. Rf = 0.37 (CH3OH : benzene 1 : 5, v/v).
[α]20D = ñ19.4. 1H NMR (300 MHz, CDCl3, δ,
ppm): 6.62 (s, 1H, Ar-H4), 6.53 (s, 1H, Ar-H6),
4.12ñ3.95 (m, 2 H, Ar-O-CH2), 3.64 (dd, J = 10.6,
J = 4.1 Hz, 1H, CH-CHH-OH), 3.32 (dd, J = 10.6,
J = 6.4 Hz, 1H, CH-CHH-OH), 3.17ñ3.04 (m, 1H,
CHH-NH), 3.01ñ2.89 (m, 1H, CHH-NH),
2.70ñ2.58 (m, 1H, NH-CH-CH2-OH), 2.28 (s, 3H,
Ar-CH3), 2.23 (s, 3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3),
1.61ñ1.38 (m, 2H, CH-CH2-CH3), 0.95 (t, J = 7.4 Hz,
3H, CH-CH2-CH3). Analysis: calcd.: C, 71.66; H,
10.02; N, 5.57%; found: C, 71.01; H, 9.80; N, 5.37%.
S-(+)-2N-[(2,3,5-trimethylphenoxy)ethyl]amino-
butan-1-ol [XIV]
Yield 56%; C15H25NO2, M.w. = 251.35, m.p.:
47ñ49OC. Rf = 0.37 (CH3OH : benzene 1 : 5, v/v).
[α]20D = 22.2. 1H NMR (300 MHz, CDCl3, δ, ppm):
6.62 (s, 1H, Ar-H4), 6.53 (s, 1H, Ar-H6), 4.13ñ3.99
(m, 2H, Ar-O-CH2), 3.67 (dd, J = 10.8, J = 4.0 Hz,
1H, CH-CH2-OH), 3.36 (dd, J = 10.8, J = 6.4 Hz,
1H, CH-CH2-OH), 3.20ñ3.08 (m, 1H, CH2-NH),
3.04ñ2.94 (m, 1H, CH2-NH), 2.75ñ2.64 (m, 1H,
NH-CH-CH2-OH), 2.27 (s, 3H, Ar-CH3), 2.23 (s,
3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3), 1.67ñ1.42 (m, 2H,
CH-CH2-CH3), 0.96 (t, J = 7.4 Hz, 3H, CH-CH2-CH3).
Analysis: calcd.: C, 71.66; H, 10.02; N, 5.57%;
found: C, 71.31; H, 9.95; N, 5.48%.
R,S-trans-2N-[(2,3,5-trimethylphenoxy)ethyl]
aminocyclohexan-1-ol [XV] 
Yield 70%; C17H27NO2, M.w. = 277.47, m.p.:
117ñ119OC. Rf = 0.54 (CH3OH : benzene 1 : 5, v/v).
Log P = 3.36 ± 0.27. 1H-NMR (300 MHz, CDCl3, δ,
ppm): 6.59 (d, J = 8.8, 1H, Ar-H4); 6.56 (d, J = 3.0,
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1H, Ar-H6); 4.62 (d, J = 5.1 Hz, 1H, OH); 4.04ñ3.98
(m, 1H, Ar-O-CHH); 3.94ñ3.86 (m, 1H, Ar-O-CHH);
3.13ñ3.04 (m, 1H, HO-CH); 2.97ñ2.89 (m, 1H,
CHH-N); 2.86ñ2.78 (m, 1H, CHH-N); 2.23ñ2.15
(m, 1H, NH); 2.21 (s, 3H, Ar-CH3); 2.15 (s, 3H, 
Ar-CH3); 2.02 (s, 3H, Ar-CH3); 1.96ñ1.88 (m, 1H,
cyclohex.); 1.83ñ1.75 (m, 1H, cyclohex.); 1.66ñ1.54
(m, 2H, cyclohex); 1.24ñ1.09 (m, 3H, cyclohex.);
0.96ñ0.86 (m, 1H, cyclohex.). Analysis: calcd.: C,
73.58; H, 9.81; N, 5.07%; found: C, 72.83; H, 9.48;
N, 5.24%.
R,S-trans-4N-[(2,3,5-trimethylphenoxy)ethyl]
aminocyclohexan-1-ol [XVI]
Yield 68%; C17H27NO2, M.w. = 277.41 m.p.:
109ñ111OC. Rf = 0.45 (CHCl3 : CH3OH 1 : 1, v/v).
Log P = 3.22 ± 0.26. 1H NMR (500 MHz, DMSO, δ,
ppm): 6.62 (s, 1H, Ar-H4), 6.53 (s, 1H, Ar-H6), 4.06
(t, J = 5.3 Hz, 2H, O-CH2-CH2-N), 3.71ñ3.56 (m,
1H, CH-OH), 3.06 (t, J = 5.2 Hz, 2 H, O-CH2-CH2-N),
2.68ñ2.51 (m, 1H, CH-NH), 2.27 (s, 3H, Ar-CH3),
2.22 (s, 3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3), 2.00 (m,
4H, cyclohex-H2,6), 1.88 (bs, 2H, OH, NH),
1.43ñ1.12 (m, 4H, cyclohex-H3,5). Analysis: calcd.:
C, 73.61; H, 9.81; N, 5.05%; found: C, 73.59; H,
9.89; N, 5.06%.
R,S-2N-[(2,3,5-trimethylphenoxy)ethyl]amino-1-
phenylethan-1-ol hydrochloride [XVII]
Yield 58%; C19H26NO2Cl, M.w. = 335.86;
m.p.: 146ñ148OC. Rf = 0.36 (CH3OH : benzene 1 : 5,
v/v). Log P = 4.00 ± 0.30. 1H-NMR (300 MHz,
DMSO, δ, ppm): 9.37 (bs, 2H, NH2+); 7.48ñ7.23 (m,
5H, Ar-H); 6.62 (d, J = 4.7 Hz, 2H, Ar-H); 6.26 (d,
J = 4.7 Hz, 1H, OH); 5.13ñ5.00 (m, 1H, CH);
4.34ñ4.19 (m, 2H, O-CH2); 3.40ñ3.03 (m, 4H, CH2-N);
2.22 (s, 3H, Ar-CH3); 2.15 (s, 3H, Ar-CH3); 2.02 (s,
3H, Ar-CH3). Analysis: calcd.: C, 67.94; H, 7.80; N,
4.17%; found: C, 67.91; H, 7.8042; N, 4.02%.
Pharmacology
Evaluation of anticonvulsant activity and neu-
rotoxicity was carried out according to the
Anticonvulsant Screening Program (ASP) at
National Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of Health
(NIH), Rockville, USA. Tests were performed in
mice (adult male Carworth Farms No. 1) after
intraperitoneal (i.p.) administration and/or in rats
(Sprague-Dawley) after oral (p.o.) administration.
The tested compounds were administered as solu-
tions or suspensions in 0.5% methylcellulose. The
total volume of used suspension was 0.01 mL/1 g
b.w. for mice and 0.04 mL/10 g b.w. for rats. Initial
dosage for evaluation in mice was 30, 100, and 300
mg/kg, and in rats 30 mg/kg. Tests were performed
at certain time points after administration of the
compound i.e., at 0.5 and 4.0 h after i.p. administra-
tion or at 0.25, 0.5, 1.0, 2.0 and 4.0 h after p.o.
administration. All procedures were published else-
where (15, 17), below we provide short description
of the experiments.
Maximal electroshock (MES)
At certain time after administration of the test-
ed compound, 60 Hz alternating current at 50 mA
for mice or 150 mA for rats was delivered for 0.2 s
via corneal electrodes. Protection in MES test was
defined as the abolition of the hindlimb tonic exten-
sion component of the seizure (15, 17).
Subcutaneous pentetrazole induced seizures
(scMet)
The scMet was conducted in mice at certain time
after administration of the tested compound by subcu-
taneous administration of pentetrazole dissolved in
0.9% NaCl solution at the dose of 85 mg/kg. The ani-
mal was placed in isolation cage and observed for next
30 min. Failure of observing even a threshold seizure
(a single episode of clonic spasm which remains at
least 5 s) was classified as protection (15, 17).
Neurotoxicity assays (TOX)
Neurotoxicity in mice was measured by the
rotarod test. A mouse was placed on a 1 inch diam-
eter knurled plastic rod rotating at 6 rpm.
Neurotoxicity was indicated by the inability of the
animal to maintain equilibrium on the rod for at least
1 min in each of the three trials. In rats, neurological
deficit was indicated by ataxia, loss of placing
response and muscle tone (15, 17).
6 Hz psychomotor seizure test
The 6 Hz model test was carried out according
to the protocol originally described by Brown et al.
(18) and more recently by Barton et al. (19) and
Kaminski et al. (20). 6 Hz test was performed in
mice. Seizures were induced by delivering 0.2 ms
pulses of electric current at 6 Hz and 32 mA for 3 s
via corneal electrodes. Untreated animals display
seizures after such stimulation described as minimal
clonic phase, whereas mice not displaying this
behavioral are considered protected.
RESULTS
The synthesis of the tested compounds consist-
ed of O-alkylation of the appropriate substituted
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Table 2. Anticonvulsant activity of the tested compounds (IñXVII) (mice, i.p.).
Dose MES a) scMet a) TOX b)
ASPCompound [mg/kg 
class c)b.w.] 0.5 h 4.0 h 0.5 h 4.0 h 0.5 h 4.0 h
I 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 3/3 0/3 0/1 0/1 8/8 1/4
300 | | | | 4/4 | 
II 30 0/1 0/1 0/1 0/1 2/4 1/2 4
100 3/3 3/3 0/1 0/1 8/8 1/4
300 1/1 | 0/1 | 4/4 | 
III 30 0/1 0/1 0/1 0/1 0/4 0/4 1
100 3/3 0/3 0/1 0/1 8/8 0/4
300 | | | | 4/4 | 
IV 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 3/3 0/3 0/1 0/1 8/8 0/4
100 1/1 | | | 4/4 | 
VI 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 7/8 0/4
300 0/1 0/1 0/1 0/1 3/4 1/2
VII 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 2/2 0/3 0/1 0/1 8/8 0/4
300 | | | | 4/4 | 
VIII 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 2/2 0/3 0/1 0/1 8/8 0/4
300 | | | | 4/4 | 
IX 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 1/3 0/3 | 0/1 4/8 0/4
300 | 0/1 | | 4/4 0/2 
X 30 0/1 0/1 0/1 0/1 3/4 1/2 4  
100 3/3 0/3 0/1 0/1 8/8 1/4
300 | | | | 4/4 | 
XI 3 0/4 | | | 0/4 | 4
10 0/4 | | | 0/4 | 
30 1/1 0/1 0/1 1/4 1/2
100 3/3 2/2 0/1 8/8 1/3
300 | | | | 4/4 | 
XII 3 0/4 | | | 0/4 | 1
10 0/4 | | | 0/4 | 
30 1/1 0/1 0/1 0/1 0/4 0/2
100 3/3 1/3 0/1 0/1 7/8 0/4
300 | 0/1 | | 4/4 0/2
XIII 3 | | | | | | 1
10 0/4 | | | 0/4 | 
30 1/1 0/1 0/1 0/1 0/4 0/2
100 2/3 1/3 0/1 0/1 4/8 0/4
300 | | | | 4/4 |
XIV 3 0/4 | | | 0/4 | 4  
10 0/4 | | | 0/4 | 
30 1/1 0/1 0/1 0/1 3/4 0/2
100 3/3 0/3 | 0/1 7/8 0/4
300 | | | | 4/4 | 
| XV 3 0/4 | | | 0/4 | 4
10 0/4 | | | 0/4 | 
30 1/1 0/1 0/1 0/1 1/4 0/2
100 3/3 0/3 0/1 0/1 7/8 1/4
300 | | | | 4/4 | 
XVI 30 0/1 0/1 0/1 0/1 0/4 0/2 1
100 3/3 0/3 0/1 0/1 8/8 0/4
300 | | | | 4/4 | 
XVII 30 0/1 0/1 0/1 0/1 3/4 1/2 4  
100 3/3 1/3 0/1 0/1 8/8 4/4
300 1/1 | | 0/1 4/4 1/1
a) Number of animals protected / number of animals tested; b) number of animals exhibiting toxicity / number of animals tested in the rotorod
test; c) ASP classification: 1 ñ anticonvulsant activity at dose 100 mg/kg or less; 2 ñ anticonvulsant activity at doses greater than 100 mg/kg;
3 ñ compound inactive at 300 mg/kg; 4 ñ compound either active or inactive but toxic at dose of 30 mg/kg; | ñ the compound was not test-
ed in the particular conditions.
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phenol by means of 2-chloroethanol or 3-chloro-
propan-1-ol in the first step. Then, the obtained 2-
phenoxyalkanols were converted to bromides by
means of phosphorus tribromide. Finally, the
obtained bromide derivatives were used in N-alkyla-
tion of chosen aminoalkanols. 
After confirmation of structure and chemical
purity, the synthesized compounds were subjected
to anticonvulsant and neurotoxicity evaluation
according to the protocols within Anticonvulsant
Screening Program (ASP). Pharmacological tests
were performed at National Institute of Neurological
Disorders and Stroke, National Institutes of Health,
Rockville, USA. Most of the compounds were qual-
ified to standard procedures and tested in mice after
i.p. administration. The results are shown in Table 2.
The protective activity in MES was found for major-
ity of the compounds. Most of substances showed
full protection at the dose 100 mg/kg. Compounds
XIñXV were also active at 30 mg/kg. Considering
scMet evaluation, compound XI was the only one in
the series which showed protection. Anticonvulsant
properties of the tested substances were in all cases
accompanied by neurotoxicity, especially at the
doses of 100 and 300 mg/kg. Most promising com-
pounds, XII, XIII, and XIV proved anticonvulsant
activity at 30 mg/kg and no neurotoxicity at the
same dose. They are derivatives of 2-aminobutan-1-
ol ñ the racemate and the two enantiomers.
Additional tests in rats after oral administration
(p.o.) were performed for compounds XIII and XV,
results are presented in Table 3. Both substances
caused no neurological impairment at all tested time
points. Interestingly, compound XIII showed pro-
tection until 1.0 h after administration while XV
only at 2.0 and 4.0 h, whereas in mice i.p. evaluation
both compounds were active at 0.5 h. Compound
XIII was also used in a more advanced test in order
to find ED50 value. ED50 indicates dose in which the
compound is effective in 50% of tested animals (17).
The dose was found to be more than 120 mg/kg b.
w. (rats, p.o.) while tested after 1 h of administration
of the compound. 
Compound V was qualified to modified proto-
cols and was tested initially in 6 Hz model. The
obtained results were not good enough to have the
Table 3. Anticonvulsant activity of compounds XIII and XV tested in rats, p.o.
Compound Test Dose Time [h]
[mg/kg b.w.]      0.25 0.5 1.0 2.0 4.0
XIII MESa) 30 1/4 3/4 2/4 0/4 0/4  
ED50 (1 h) > 
120 TOXa) 30 0/4 0/4 0/4 0/4 0/4
MESa) 30 0/4 0/4 0/4 1/4 2/4
XV
TOXa) 30 0/4 0/4 0/4 0/4 0/4
a) Number of animals protected / number of animals tested in anticonvulsant or neurotoxicity assays.
Table 4. Anticonvulsant activity in 6-Hz test of compounds I and V (mice, i.p.).
Compound Test Dose Time [h]
[mg/kg b.w.]      0.25 0.5 1.0 2.0 4.0
6-Hz a) 30 1/4 3/4 2/4 0/4 0/4  
I 
TOX b) 30 0/4 0/4 0/4 0/4 0/4
6-Hz a) 30 0/4 0/4 0/4 1/4 2/4
V
TOX b) 30 0/4 0/4 0/4 0/4 0/4
a) Number of animals protected / number of animals tested; b) number of animals exhibiting toxicity / number of animals tested in the rotorod
test.
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compound tested in MES. On the other hand, com-
pound I was qualified for 6 Hz evaluation after suc-
cessful MES screen. Results of 6 Hz model are
shown in Table 4. Both compounds showed some
protection.
DISCUSSION AND CONCLUSION
The anticonvulsant activity and neurotoxicity
of all synthesized compounds IñXVII were evaluat-
ed according to the protocols of ASP, NIH, USA
(15, 17). The reported series of compounds was
characterized by good anticonvulsant activity in
MES (mice, i.p.). It is visible that among aminoalka-
nols used as moieties ñ aminopropanol and
aminobutanol with various configuration are more
promising compared to more bulky moieties such as
2-amino-1-phenylethanol ñ compounds IñIV and
XñXIV are the most active. Within this group, the
use of ethyl or propyl linker does not make any sig-
nificant difference in terms of activity ñ comparing
compounds II and VII as well as III and VIII in
pairs in Table 2.
In terms of substitution of the phenyl ring it is
clearly visible that 2,3,5-trimethyl derivatives are
more active than 2,5-dimethyl ones ñ the most
active compound is XIII ñ R-2N-(2,3,5-trimethyl-
phenoxy)ethyl]aminobutan-1-ol which was
advanced to testing in rats, p.o.
The activity of IñXVII was mostly accompa-
nied by neurotoxicity which excluded the com-
pounds from further testing. The important factors
in the group are the values of calculated partition
coefficient (log P) ranging from 2.22 ± 0.28 to 4.00
± 0.30. Literature references indicate that in order to
reach optimum activity within the central nervous
system log P as a measure of lipophilicity should be
around 2 (21, 22). In case of some more lipophilic
compounds one of the reason of neurotoxicity might
be high values of log P. 
In terms of structure-anticonvulsant activity
relationship, the obtained results in the reported
series of compounds combined together with former
results indicated that parameters such as type of sub-
stituents and their location in the phenyl ring, the
aminoalkanol moiety, configuration may have
impact on anticonvulsant activity. In conclusion, in
the light of formerly published results, the conduct-
ed research confirmed that aroxyalkyl derivatives of
aminoalkanols are an interesting group in terms of
anticonvulsant activity, although 2,5-dimethyl and
2,3,5-trimethyl derivatives exhibit concomitant neu-
rotoxicity. 
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